In a phase III study in the first line setting, afatinib was shown to be superior to chemotherapy in EGFR mutant NSCLC with a progression free survival (PFS) of 11.1 months vs. 6.9 months in the chemotherapy group (HR 0.58) [52]. Here, EGFR is linked to non-small cell lung carcinoma.